New drug combo vs docetaxel for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new two-drug combination (HS-20093 plus adebrelimab) against the standard chemo docetaxel for people with advanced non-squamous non-small cell lung cancer who have already had treatment. It aims to see if the new combination works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You must have advanced or metastatic non-squamous non-small cell lung cancer that has been treated before
- You must have at least one tumor that can be measured on scans
- You must be able to care for yourself (ECOG score 0 or 1)
- Your organs (like liver, kidneys, blood) must be working well enough
- You must not have untreated or uncontrolled brain metastases
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new drug combination (SYS6010 plus enlonstobart) works better than standard immunotherapy with chemotherapy for patients with advanced non-small cell lung cancer. You may qualify if you have not received prior cancer treatment and have a specific marker (PD-L1) on your tumor.
This trial tests a new combination treatment for people with advanced non-small cell or small cell lung cancer that cannot be removed by surgery or cured with standard treatments. It aims to see if the combination is safe and effective.
This trial tests a new drug (RC148) plus chemotherapy against another drug (Tislelizumab) plus chemotherapy for people with a type of lung cancer called squamous non-small cell lung cancer that has spread or can't be removed. It's for those who haven't had treatment for advanced disease yet.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a new drug called SYS6010 against a standard chemotherapy (docetaxel) for people with a certain type of advanced lung cancer that does not have an EGFR mutation and has stopped responding to previous treatments. The goal is to see which treatment works better.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.